The last time I spoke about Cartesian Therapeutics (RNAC) it was in a Seeking Alpha article entitled "Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data." There, I wrote about ...

A look at the shareholders of Cartesian Growth Corporation (NASDAQ:GLBL) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

Median interval between end of initial treatment course and first retreatment infusion was 16.6 months No new safety signals reported; safety profile consistent with previously reported data Topline ...

Track Cartesian Growth Corporation II Class A Ordinary Shares live price, charts, and news. Analyze Cartesian Growth Corporation II Class A Ordinary Shares forecasts, financials, technical indicators, ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, today announced that it has received the required ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, announced today that in an extraordinary general meeting on ...